Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Biologic therapy.

National Cancer Institute, Bethesda, MD, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Bethesda, MD
Treatments:Biologic therapyHospital:National Cancer Institute
Drugs:Journal:Link
Date:Dec 2012

Description:

Patients:
Patients in this phase 2 study were divided into 2 groups based on their particular form of brain cancer. Group A consisted of 32 glioblastoma multiforme patients with a median age of 48 years and 63% male. Group B had 32 anaplastic glioma patients with a median age of 41 years and 75% male.

Treatment:
Patients in both groups were treated with the biologic therapy agent vandetanib, which is a VEGF inhibitor that interferes with tumor blood supply.

Toxicities:
This study reported toxicities observed in both patient groups combined. There was one treatment-related death due to brain hemorrhage. Grade 4 lymphopenia, fatigue, and skin reactions were also reported.

Results:
The median overall survival rates for group A and B were 6.3 and 7.6 months, respectively.

Support:
Study drug was supplied by AstraZeneca.

Correspondence: Dr. Teri N. Kreisl; email: [email protected]



Back